Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10 - PubMed (original) (raw)
Clinical Trial
Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10
Li-Yan Khor et al. Int J Radiat Oncol Biol Phys. 2008.
Abstract
Purpose: The RI-alpha regulatory subunit of protein kinase A type 1 (PKA) is constitutively overexpressed in human cancer cell lines and is associated with active cell growth and neoplastic transformation. This report examined the association between PKA expression and the endpoints of biochemical failure (BF), local failure (LF), distant metastasis (DM), cause-specific mortality (CSM), and overall mortality in men treated with radiotherapy, with or without short-term androgen deprivation in Radiation Therapy Oncology Group trial 86-10.
Methods and materials: Pretreatment archival diagnostic tissue samples from 80 patients were stained for PKA by immunohistochemical methods from a parent cohort of 456 cases. PKA intensity was scored manually and by image analysis. The Cox proportional hazards model for overall mortality and Fine and Gray's regression models for CSM, DM, LF and BF were then applied to determine the relationship of PKA expression to the endpoints.
Results: The pretreatment characteristics of the missing and determined PKA groups were not significantly different. On univariate analyses, a high PKA staining intensity was associated with BF (image analysis, continuous variable, p = 0.022), LF (image analysis, dichotomized variable, p = 0.011), CSM (manual analysis, p = 0.037; image analysis, continuous, p = 0.014), and DM (manual analysis, p = 0.029). On multivariate analyses, the relationships to BF (image analysis, continuous, p = 0.03), LF (image analysis, dichotomized, p = 0.002), and DM remained significant (manual analysis, p = 0.018). In terms of CSM, a trend toward an association was seen (manual analysis, p = 0.08; image analysis, continuous, p = 0.09).
Conclusion: PKA overexpression was significantly related to patient outcome and is a potentially useful biomarker for identifying high-risk prostate cancer patients who might benefit from a PKA knockdown strategy.
Conflict of interest statement
Conflict of Interest: None
Figures
Figure 1
Relationship of PKA expression by manual (panel A) and dichotomized ACIS intensity score (B) to distant metastasis.
Figure 1
Relationship of PKA expression by manual (panel A) and dichotomized ACIS intensity score (B) to distant metastasis.
Similar articles
- The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.
Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU, Sandler HM. Pollack A, et al. Clin Cancer Res. 2009 Sep 1;15(17):5478-84. doi: 10.1158/1078-0432.CCR-08-2704. Epub 2009 Aug 25. Clin Cancer Res. 2009. PMID: 19706804 Free PMC article. Clinical Trial. - Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM. Pollack A, et al. J Clin Oncol. 2004 Jun 1;22(11):2133-40. doi: 10.1200/JCO.2004.09.150. J Clin Oncol. 2004. PMID: 15169799 - COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Dicker AP. Khor LY, et al. Lancet Oncol. 2007 Oct;8(10):912-20. doi: 10.1016/S1470-2045(07)70280-2. Epub 2007 Sep 18. Lancet Oncol. 2007. PMID: 17881290 Free PMC article. Clinical Trial. - MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A. Khor LY, et al. J Clin Oncol. 2009 Jul 1;27(19):3177-84. doi: 10.1200/JCO.2008.19.8267. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470936 Free PMC article. Clinical Trial. - Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M, Reddy CA, Zippe C, Klein EA. Kupelian PA, et al. Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):704-11. doi: 10.1016/s0360-3016(01)02778-x. Int J Radiat Oncol Biol Phys. 2002. PMID: 11849793
Cited by
- Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer.
Bennett L, Jaiswal PK, Harkless RV, Long TM, Gao N, Vandenburg B, Selman P, Durdana I, Lastra RR, Vander Griend D, Adelaiye-Ogala R, Szmulewitz RZ, Conzen SD. Bennett L, et al. Mol Cancer Ther. 2024 Apr 2;23(4):552-563. doi: 10.1158/1535-7163.MCT-22-0479. Mol Cancer Ther. 2024. PMID: 38030378 Free PMC article. - The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes.
Gulliver C, Huss S, Semjonow A, Baillie GS, Hoffmann R. Gulliver C, et al. Cancers (Basel). 2022 Dec 30;15(1):262. doi: 10.3390/cancers15010262. Cancers (Basel). 2022. PMID: 36612262 Free PMC article. - Phosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor.
Dagar M, Singh JP, Dagar G, Tyagi RK, Bagchi G. Dagar M, et al. J Biol Chem. 2019 May 31;294(22):8699-8710. doi: 10.1074/jbc.RA119.007420. Epub 2019 Apr 16. J Biol Chem. 2019. PMID: 30992362 Free PMC article. - Investigation of the molecular mechanisms underlying postoperative recurrence in prostate cancer by gene expression profiling.
Yajun C, Yuan T, Zhong W, Bin X. Yajun C, et al. Exp Ther Med. 2018 Jan;15(1):761-768. doi: 10.3892/etm.2017.5510. Epub 2017 Nov 14. Exp Ther Med. 2018. PMID: 29399083 Free PMC article. - Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.
Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Pollack A, et al. J Natl Cancer Inst. 2017 Feb 1;109(2):1-8. doi: 10.1093/jnci/djw232. J Natl Cancer Inst. 2017. PMID: 28376214 Free PMC article. Clinical Trial.
References
- Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res. 1990;50:7093–7100. - PubMed
- Miller WR, Hulme MJ, Cho-Chung YS, et al. Types of cyclic AMP binding proteins in human breast cancers. Eur J Cancer. 1993;29A:989–991. - PubMed
- Shi SS, He ZG, Shao K, et al. Relationship between overexpression of the RIalpha subunit of the cAMP-dependent protein kinase and clinicopathological features of lung cancer. Zhonghu Zhong Liu Za Zhi. 2004;26:547–550. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA 101984-01/CA/NCI NIH HHS/United States
- CA 006927/CA/NCI NIH HHS/United States
- CA 21661/CA/NCI NIH HHS/United States
- R01 CA101984-05/CA/NCI NIH HHS/United States
- R01 CA101984/CA/NCI NIH HHS/United States
- U10 CA021661/CA/NCI NIH HHS/United States
- CA 32115/CA/NCI NIH HHS/United States
- P30 CA006927/CA/NCI NIH HHS/United States
- U10 CA032115/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous